Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
20 Febrero 2024 - 6:30AM
Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a
clinical-stage TechBio company specializing in developing
AI-Immunology™ powered vaccines, announces the successful
completion of the initial phases of its vaccine collaboration with
MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA). The
vaccine development project combines both organizations' unique
capabilities and know-how.
Evaxion's Chief Executive Officer Christian
Kanstrup expresses enthusiasm, "In September last year, we
announced a collaboration with a leading pharma company, and today
we are proud to present that this collaborator is MSD. Further, we
are excited about the successful conclusion of the vaccine target
discovery and design phases of the collaboration and are eagerly
awaiting the next phase. We strongly believe that this
collaboration will further validate the power of our AI-Immunology™
platform and contribute to improving lives by designing unique
vaccines addressing serious medical conditions."
Using Evaxion's proprietary platform,
AI-Immunology™, Evaxion has identified novel vaccine targets
against a bacterial pathogen causing severe health issues. The
conclusion of the antigen discovery and design phases marks a
significant milestone for the development of the vaccine candidate,
EVX-B3.
Tarit Mukhopadhyay, Vice President, Head of
Infectious Diseases and Vaccine Discovery at MSD Research
Laboratories, said: "At MSD, we are exploring new ways to apply AI
technologies across the discovery-development continuum. We are
excited to further advance our work with the Evaxion team."
For information about the initial collaboration
announcement, please refer to our previous press release.
About EVX-B3
EVX-B3 is a bacterial vaccine development
project carried out in collaboration with MSD (tradename of Merck
& Co., Inc., Rahway, NJ, USA). The project aims to address a
pressing global medical issue by targeting an undisclosed bacterial
pathogen for which no preventive or curative options are currently
available.
About AI-Immunology™
AI-Immunology™ is a scalable and adaptable
artificial intelligence technology platform at the forefront of
vaccine discovery for infectious diseases and cancers. By
integrating the collective power of proprietary AI models PIONEER™,
EDEN™, RAVEN™, and ObsERV™, the platform can model the complexity
of the patient's immune system. AI-Immunology™ advanced
computational modeling swiftly and uniquely identifies,
predicts, and designs vaccine candidates, revolutionizing the
landscape of immunotherapy by offering a holistic and personalized
approach to combat fast-evolving pathogens and malignant
cells.
About EVAXION
Evaxion Biotech A/S is a pioneering TechBio
company based upon its AI platform, AI-Immunology™. Evaxion's
proprietary and scalable AI prediction models harness the power of
artificial intelligence to decode the human immune system and
develop novel immunotherapies for cancer, bacterial diseases, and
viral infections. Based upon AI-Immunology™, Evaxion has developed
a clinical-stage oncology pipeline of novel personalized vaccines
and a preclinical infectious disease pipeline in bacterial and
viral diseases with high unmet medical needs. Evaxion is committed
to transforming patients' lives by providing innovative and
targeted treatment options. For more information about Evaxion and
its groundbreaking AI-Immunology™ platform and vaccine pipeline,
please visit our website.
Forward-Looking
Statement
This announcement contains forward-looking
statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. The words "target," "believe,"
"expect," "hope," "aim," "intend," "may," "might," "anticipate,"
"contemplate," "continue," "estimate," "plan," "potential,"
"predict," "project," "will," "can have," "likely," "should,"
"would," "could," and other words and terms of similar
meaning identify forward-looking statements. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various factors,
including, but not limited to, risks related to: our financial
condition and need for additional capital; our development work;
cost and success of our product development activities and
preclinical and clinical trials; commercializing any approved
pharmaceutical product developed using our AI platform technology,
including the rate and degree of market acceptance of our product
candidates; our dependence on third parties including for conduct
of clinical testing and product manufacture; our inability to enter
into partnerships; government regulation; protection of our
intellectual property rights; employee matters and managing growth;
our ADSs and ordinary shares, the impact of international
economic, political, legal, compliance, social and business
factors, including inflation, and the effects on our business
from the worldwide ongoing COVID-19 pandemic and the ongoing
conflict in the region
surrounding Ukraine and Russia and the Middle
East; and other uncertainties affecting our business
operations and financial condition. For a further discussion
of these risks, please refer to the risk factors included in our
most recent Annual Report on Form 20-F and other
filings with the U.S. Securities and Exchange Commission
(SEC), which are available
at www.sec.gov. We do not assume any
obligation to update any forward-looking statements except as
required by law.
Contact Information
Evaxion Biotech A/S
Christian Kanstrup
Chief Executive Officer
cka@evaxion-biotech.com
Source: Evaxion Biotech
Evaxion Biotech AS (NASDAQ:EVAX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Evaxion Biotech AS (NASDAQ:EVAX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024